logo inserm ifrb fondateurCC logoUSPN

Publications of INSERM UMR 1125


  • Antineuronal antibodies in sporadic late-onset cerebellar ataxia. Bürk K, Wick M, Roth G, Decker P, Voltz, R.  J Neurol, 2010, 257:59-62.
  • Interleukin-6: from identification of the cytokine to development of targeted treatments. Assier E, Boissier MC, Dayer JM.  Joint Bone Spine. 2010 ;77:532-6.
  • Blood vessels, a potential therapeutic target in rheumatoid arthritis? Semerano L, Clavel G, Assier E, Denys A, Boissier MC. Joint Bone Spine. 2011;78:118-23.
  • Intra-articular electrotransfer of mouse soluble tumour necrosis factor receptor in a murine model of rheumatoid arthritis. Denys A, Thiolat A, Descamps D, Lemeiter D, Benihoud K, Bessis N, Boissier MC J Gene Med. 2010;12:659-68.
  • Early activation of invariant natural killer T cells in a rheumatoid arthritis model and application to disease treatment. Miellot-Gafsou A, Biton J, Bourgeois E, Herbelin A, Boissier MC, Bessis N. Immunology. 2010 ;130:296-306.


  • Neurological symptoms in patients with biopsy proven celiac disease. Bürk K, Farecki ML, Lamprecht G, Roth G, Decker P, Weller M, Rammensee HG, Oertel WHO. Mov Disord, 2009, 24:2358-62.
  • Neutrophils, dendritic cells and chromatin-mediated pathogenesis in systemic lupus erythematosus. Lindau D, Decker P.  Autoimmunity, 2009, 42:254-6.
  • Chromatin modifications, oxidative stress and nucleosome autoantibodies. In: The epigenetics of autoimmune diseases. Erbacher A, Decker P.  2009, 119-34. Editor, Moncef Zouali; Publisher, Wiley Inc., New York.
  • Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis. Delavallée L, Semerano L, Assier E, Vogel G, Vuagniaux G, Laborie M, Zagury D, Bessis N, Boissier MC.  Arthritis Res Ther. 2009;11(6):R195. Epub 2009 Dec 23.
  • Regulatory T cells (Treg) in rheumatoid arthritis. Boissier MC, Assier E, Biton J, Denys A, Falgarone G, Bessis N. Joint Bone Spine. 2009;76:10-4.
  • No evidence of major effects in several Toll-like receptor gene polymorphisms in rheumatoid arthritis. Jaen O, Petit-Teixeira E, Kirsten H, Ahnert P, Semerano L, Pierlot C, Cornelis F, Boissier MC, Falgarone G; European Consortium on Rheumatoid Arthritis Families.  Arthritis Res Ther. 2009;11:R5. Epub 2009 Jan 13.


  • Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA. Kloss M*, Decker P*, Baltz K, Baessler T, Jung G, Rammensee HG, Steinle A, Krusch M, Salih H.  J Immunol, 2008, 181: 6711-19. *The first two authors contributed equally to this work.
  • The PDE4 inhibitor rolipram prevents NF-kappaB binding activity and proinflammatory cytokine release in human chorionic cells. Hervé R, Schmitz T, Evain-Brion D, Cabrol D, Leroy MJ, Méhats C. J Immunol. 2008 Aug 1;181(3):2196-202.
  • Dendritic cells modulated by innate immunity improve collagen-induced arthritis and induce regulatory T cells in vivo. Jaen O, Rullé S, Bessis N, Zago A, Boissier MC, Falgarone G. . Immunology. 2009;126:35-44..
  • Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis. Launois R, Payet S, Saidenberg-Kermanac'h N, Francesconi C, França LR, Boissier MC. Joint Bone Spine. 2008;75:688-95.
  • Shifting the imbalance from Th1/Th2 to Th17/treg: the changing rheumatoid arthritis paradigm.  Boissier MC, Assier E, Falgarone G, Bessis N. Joint Bone Spine. 2008;75:373-5.
  • ltrasound and Doppler micro-imaging in a model of rheumatoid arthritis in mice. Clavel G, Marchiol-Fournigault C, Renault G, Boissier MC, Fradelizi D, Bessis N. U Ann Rheum Dis. 2008 ;67:1765-72.
  • Emerging applications of anticytokine vaccines. Delavallée L, Assier E, Semerano L, Bessis N, Boissier MC. . Expert Rev Vaccines. 2008;7:1507-17.
  • Vaccination with cytokines in autoimmune diseases. Delavallée L, Assier E, Denys A, Falgarone G, Zagury JF, Muller S, Bessis N, Boissier MC  Ann Med. 2008;40:343-51.
  • Arly and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha. Delavallée L, Le Buanec H, Bessis N, Assier E, Denys A, Bizzini B, Zagury D, Boissier MC. E Ann Rheum Dis. 2008;67:1332-8.


  • Synoviocytes infection by AAV is neutralized by human synovial fluid from arthritis patients and depends on AAV serotype. Boissier M-C, Lemeiter D., Valvason C Clavel G, Laroche L. , Begue T., and Bessis N. SHum Gene Ther, 2007 , 18 : 525-35.
  • Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clavel C, Bessis N, Fardellone P, Othmane M, Menard JF, Pouplin S, Boumier P, Vittecoq O, Le Loêt X, Boissier MC.  Clin Immunol,2007, 124: 158-64.
  • Circulating nucleosomes due to a defective clearance of dying cells: consequences in systemic lupus erythematosus. Erbacher A, Rönnefarth V, Decker P.  Autoimmunity, 2007, 40:311-14.

More Articles ...

USPN Campus de Bobigny

tour illustration bobigny

web li2p V3